Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Common Equity (2021 - 2025)

Historic Common Equity for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $535.4 million.

  • Kiniksa Pharmaceuticals International's Common Equity rose 2251.16% to $535.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $535.4 million, marking a year-over-year increase of 2251.16%. This contributed to the annual value of $438.4 million for FY2024, which is 9.18% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Common Equity stood at $535.4 million for Q3 2025, which was up 2251.16% from $495.0 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Common Equity's 5-year high stood at $535.4 million during Q3 2025, with a 5-year trough of $153.5 million in Q2 2022.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Common Equity had a median value of $405.1 million in 2023 and averaged $362.2 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Common Equity tumbled by 3858.65% in 2022, and later skyrocketed by 16819.03% in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Common Equity stood at $185.0 million in 2021, then skyrocketed by 114.09% to $396.1 million in 2022, then increased by 10.78% to $438.8 million in 2023, then decreased by 0.09% to $438.4 million in 2024, then rose by 22.11% to $535.4 million in 2025.
  • Its Common Equity was $535.4 million in Q3 2025, compared to $495.0 million in Q2 2025 and $457.5 million in Q1 2025.